Editas Medicine, Inc.
EDIT evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $465.3M
- Lead Asset:
- CASGEVY (exagamglogene autotemcel) (Approved)
What it means
What to watch
Prepared research question
What matters most for EDIT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EDIT
Editas Medicine, Inc. is a publicly traded biotechnology company focused on developing in vivo CRISPR-based gene editing therapies for serious diseases, with its lead candidate EDIT-401 targeting LDL cholesterol reduction.
Key risk: Preclinical stage
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials for Editas Medicine, Inc..
Editas Medicine, Inc. is a publicly traded biotechnology company focused on developing in vivo CRISPR-based gene editing therapies for serious diseases, with its lead candidate EDIT-401 targeting LDL cholesterol reduction.
- Editas Medicine is a pioneering gene editing company using CRISPR technology to develop transformative genomic medicines for serious diseases [sec · filed 2026-08-31].
- In December 2024, the company transitioned to a fully in vivo focused preclinical company, aiming for human proof-of-concept within approximately two years [sec · filed 2026-04-28].
- Lead in vivo development candidate EDIT-401 is a potential best-in-class, one-time therapy to significantly reduce LDL-cholesterol through upregulation [sec · filed 2026-08-31].
- As of 2026-06-30, the company reported cash & equivalents of $181.8M, total revenue of $11.9M, and net income of -$18.2M [sec].
- The company extended its cash runway into the third quarter of 2027 through financial discipline and an at-the-market offering facility [sec · filed 2026-04-28].
What works
- Editas has a proprietary CRISPR-based gene editing platform and a 'plug 'n play' lipid nanoparticle delivery system that can target multiple tissues, including liver and hematopoietic stem cells [sec · filed 2026-08-31].
- The company achieved a 91% corporate achievement rating for 2025 goals, indicating strong operational execution [sec · filed 2026-04-28].
- Cash runway extends into Q3 2027, providing financial stability to advance lead programs toward key milestones [sec · filed 2026-04-28].
What to weigh
- Editas is a preclinical company with no approved products; its lead candidate EDIT-401 has not yet entered human trials [sec · filed 2026-04-28].
- The company reported a net loss of -$18.2M for the period ending 2026-06-30, reflecting ongoing R&D investment without product revenue [sec].
- Forward-looking statements caution that actual results may differ materially from plans due to risks and uncertainties in preclinical studies and clinical trials [sec · filed 2026-08-31].
From the filings
Quoted directly from source documents.
Editas transitioned to a fully in vivo focused preclinical company in December 2024.
“we accelerated this strategy in December 2024 by transitioning to a fully in vivo focused preclinical company with the intent of achieving in vivo human proof-of-concept within approximately two years.”
SEC filings · April 28, 2026
EDIT-401 is the lead in vivo development candidate for LDL cholesterol reduction.
“In September 2025 we announced the nomination of our lead in vivo development candidate, EDIT-401, an experimental, potential best-i”
SEC filings · April 28, 2026
Cash runway extends into Q3 2027.
“we extended our cash runway into the third quarter of 2027”
SEC filings · April 28, 2026
Risks & what to watch (3)›
Key risks
- Preclinical stage — Company has no approved products; all programs are preclinical, with EDIT-401 yet to enter human trials [sec · filed 2026-04-28].
- Net losses — Net income of -$18.2M as of 2026-06-30 indicates ongoing cash burn without product revenue [sec].
- Execution risk — Forward-looking statements highlight risks that actual results may differ from plans for preclinical and clinical studies [sec · filed 2026-08-31].
What to watch
- Initiation of first-in-human study for EDIT-401 in 2026 and achievement of early in vivo human proof-of-concept data by end of 2026 [sec · filed 2026-05-26].
- Submission of a CTN in Australia by mid-2026 for EDIT-401 [sec · filed 2026-05-26].
- Progress of the 'plug 'n play' LNP platform for extrahepatic delivery to multiple tissues [sec · filed 2026-04-28].
- Cash runway extending into Q3 2027 and any updates on financial discipline [sec · filed 2026-04-28].
Sources: News · SEC filings · Generated October 11, 2026 · How we verify sources →
Run Editas Medicine, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Editas Medicine, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.25 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
0 buys · 5 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 12.2%
- Days to cover
- 6.6
- Shares short
- 11,941,373
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EDIT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Editas Medicine, Inc.?
Editas Medicine, Inc. is a publicly traded biotechnology company focused on developing in vivo CRISPR-based gene editing therapies for serious diseases, with its lead candidate EDIT-401 targeting LDL cholesterol reduction.
What is Editas Medicine, Inc.'s lead drug candidate?
Editas Medicine, Inc.'s most advanced tracked candidate is CASGEVY (exagamglogene autotemcel) (Approved) for Sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Who is the CEO of Editas Medicine, Inc.?
Dr. Gilmore O'Neill M.D. is the chief executive officer of Editas Medicine, Inc. (EDIT).
Where is Editas Medicine, Inc. headquartered?
Editas Medicine, Inc. (EDIT) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Editas Medicine, Inc. focus on?
Editas Medicine, Inc. develops therapies across Rare Disease, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.